1 | estimate | 8,568 |
2 | dispose | 14 |
3 | irrigate | 12 |
4 | re-estimate | 7 |
5 | trial-wide | 4 |
6 | visuals | 4 |
7 | ignite | 3 |
8 | -143.95 | 2 |
9 | 3μg/kg | 2 |
10 | abrade | 2 |
11 | amputate | 2 |
12 | analysis.in | 2 |
13 | brighten | 2 |
14 | consortium-wide | 2 |
15 | non-guideline | 2 |
16 | palatability/acceptability | 2 |
17 | smdicc | 2 |
18 | vasodilate | 2 |
19 | ᅟ | 2 |
20 | -20+/-9 | 1 |
21 | -subliminal-presentation | 1 |
22 | 0.3g/l | 1 |
23 | 0.77+ | 1 |
24 | 1.42-1.15 | 1 |
25 | 1/100th | 1 |
26 | 1/63rd | 1 |
27 | 113-fold | 1 |
28 | 115.2gy | 1 |
29 | 11weeks | 1 |
30 | 12g/kg | 1 |
31 | 13cycles | 1 |
32 | 16/454 | 1 |
33 | 18-weeks | 1 |
34 | 2-6° | 1 |
35 | 2.31+/- | 1 |
36 | 2006-06-10 | 1 |
37 | 2012.20 | 1 |
38 | 2012.date | 1 |
39 | 2013.date | 1 |
40 | 22/10 | 1 |
41 | 240mg/day | 1 |
42 | 350mg/kg/day | 1 |
43 | 39weeks | 1 |
44 | 42weeks | 1 |
45 | 61,100 | 1 |
46 | 855ng±156 | 1 |
47 | 89/324 | 1 |
48 | 900ng±159 | 1 |
49 | achieveipc | 1 |
50 | analyses.while | 1 |
51 | apap-cpap | 1 |
52 | benefits.given | 1 |
53 | cgtsq | 1 |
54 | cholesterol-indicators | 1 |
55 | condemnations | 1 |
56 | confrontations | 1 |
57 | daily-cycles | 1 |
58 | damming | 1 |
59 | deeply-depleted | 1 |
60 | delayed/non-union | 1 |
61 | dha±inhibitors | 1 |
62 | diseases/dysfunctions | 1 |
63 | disorderaffecting | 1 |
64 | establishment/release | 1 |
65 | fda-labeling | 1 |
66 | flawing | 1 |
67 | forward-propagation | 1 |
68 | g6.5 | 1 |
69 | hmgss | 1 |
70 | illness/quality | 1 |
71 | issuers | 1 |
72 | laparotomynumber | 1 |
73 | leaking/blocking | 1 |
74 | management-over | 1 |
75 | methods.a | 1 |
76 | mis-spending | 1 |
77 | misestimates | 1 |
78 | misjudgements | 1 |
79 | multitaper | 1 |
80 | near-elimination | 1 |
81 | never-use | 1 |
82 | nonopacification | 1 |
83 | ofbuccal | 1 |
84 | one-twentieth | 1 |
85 | option-in | 1 |
86 | over-estimations | 1 |
87 | over-phosphorylation | 1 |
88 | pauci-symptomaticity | 1 |
89 | r86 | 1 |
90 | rcts.one | 1 |
91 | removal/derivatization | 1 |
92 | reorientations | 1 |
93 | repair/failure | 1 |
94 | research-increases | 1 |
95 | retroposition | 1 |
96 | self-insertion | 1 |
97 | solubulization | 1 |
98 | sub-ranges | 1 |
99 | summer-like | 1 |
100 | tables.for | 1 |
101 | temperate-latitudes | 1 |
102 | thesingularity | 1 |
103 | unearthing | 1 |
104 | vitiation | 1 |
105 | yp/s | 1 |
106 | ~85-fold | 1 |
107 | £25,000/qaly | 1 |
1 | -143.95 | 2 |
2 | -20+/-9 | 1 |
3 | -subliminal-presentation | 1 |
4 | 0.3g/l | 1 |
5 | 0.77+ | 1 |
6 | 1.42-1.15 | 1 |
7 | 1/100th | 1 |
8 | 1/63rd | 1 |
9 | 113-fold | 1 |
10 | 115.2gy | 1 |
11 | 11weeks | 1 |
12 | 12g/kg | 1 |
13 | 13cycles | 1 |
14 | 16/454 | 1 |
15 | 18-weeks | 1 |
16 | 2-6° | 1 |
17 | 2.31+/- | 1 |
18 | 2006-06-10 | 1 |
19 | 2012.20 | 1 |
20 | 2012.date | 1 |
21 | 2013.date | 1 |
22 | 22/10 | 1 |
23 | 240mg/day | 1 |
24 | 350mg/kg/day | 1 |
25 | 39weeks | 1 |
26 | 3μg/kg | 2 |
27 | 42weeks | 1 |
28 | 61,100 | 1 |
29 | 855ng±156 | 1 |
30 | 89/324 | 1 |
31 | 900ng±159 | 1 |
32 | abrade | 2 |
33 | achieveipc | 1 |
34 | amputate | 2 |
35 | analyses.while | 1 |
36 | analysis.in | 2 |
37 | apap-cpap | 1 |
38 | benefits.given | 1 |
39 | brighten | 2 |
40 | cgtsq | 1 |
41 | cholesterol-indicators | 1 |
42 | condemnations | 1 |
43 | confrontations | 1 |
44 | consortium-wide | 2 |
45 | daily-cycles | 1 |
46 | damming | 1 |
47 | deeply-depleted | 1 |
48 | delayed/non-union | 1 |
49 | dha±inhibitors | 1 |
50 | diseases/dysfunctions | 1 |
51 | disorderaffecting | 1 |
52 | dispose | 14 |
53 | establishment/release | 1 |
54 | estimate | 8,568 |
55 | fda-labeling | 1 |
56 | flawing | 1 |
57 | forward-propagation | 1 |
58 | g6.5 | 1 |
59 | hmgss | 1 |
60 | ignite | 3 |
61 | illness/quality | 1 |
62 | irrigate | 12 |
63 | issuers | 1 |
64 | laparotomynumber | 1 |
65 | leaking/blocking | 1 |
66 | management-over | 1 |
67 | methods.a | 1 |
68 | mis-spending | 1 |
69 | misestimates | 1 |
70 | misjudgements | 1 |
71 | multitaper | 1 |
72 | near-elimination | 1 |
73 | never-use | 1 |
74 | non-guideline | 2 |
75 | nonopacification | 1 |
76 | ofbuccal | 1 |
77 | one-twentieth | 1 |
78 | option-in | 1 |
79 | over-estimations | 1 |
80 | over-phosphorylation | 1 |
81 | palatability/acceptability | 2 |
82 | pauci-symptomaticity | 1 |
83 | r86 | 1 |
84 | rcts.one | 1 |
85 | re-estimate | 7 |
86 | removal/derivatization | 1 |
87 | reorientations | 1 |
88 | repair/failure | 1 |
89 | research-increases | 1 |
90 | retroposition | 1 |
91 | self-insertion | 1 |
92 | smdicc | 2 |
93 | solubulization | 1 |
94 | sub-ranges | 1 |
95 | summer-like | 1 |
96 | tables.for | 1 |
97 | temperate-latitudes | 1 |
98 | thesingularity | 1 |
99 | trial-wide | 4 |
100 | unearthing | 1 |
101 | vasodilate | 2 |
102 | visuals | 4 |
103 | vitiation | 1 |
104 | yp/s | 1 |
105 | ~85-fold | 1 |
106 | £25,000/qaly | 1 |
107 | ᅟ | 2 |
1 | 0.77+ | 1 |
2 | 2.31+/- | 1 |
3 | 61,100 | 1 |
4 | 2006-06-10 | 1 |
5 | 22/10 | 1 |
6 | 2012.20 | 1 |
7 | 89/324 | 1 |
8 | 16/454 | 1 |
9 | g6.5 | 1 |
10 | 1.42-1.15 | 1 |
11 | -143.95 | 2 |
12 | 855ng±156 | 1 |
13 | r86 | 1 |
14 | -20+/-9 | 1 |
15 | 900ng±159 | 1 |
16 | methods.a | 1 |
17 | smdicc | 2 |
18 | achieveipc | 1 |
19 | deeply-depleted | 1 |
20 | 113-fold | 1 |
21 | ~85-fold | 1 |
22 | 1/63rd | 1 |
23 | abrade | 2 |
24 | trial-wide | 4 |
25 | consortium-wide | 2 |
26 | summer-like | 1 |
27 | analyses.while | 1 |
28 | non-guideline | 2 |
29 | rcts.one | 1 |
30 | repair/failure | 1 |
31 | establishment/release | 1 |
32 | dispose | 14 |
33 | never-use | 1 |
34 | 2012.date | 1 |
35 | 2013.date | 1 |
36 | irrigate | 12 |
37 | vasodilate | 2 |
38 | estimate | 8,568 |
39 | re-estimate | 7 |
40 | amputate | 2 |
41 | ignite | 3 |
42 | 12g/kg | 1 |
43 | 3μg/kg | 2 |
44 | mis-spending | 1 |
45 | unearthing | 1 |
46 | leaking/blocking | 1 |
47 | fda-labeling | 1 |
48 | damming | 1 |
49 | disorderaffecting | 1 |
50 | flawing | 1 |
51 | 1/100th | 1 |
52 | one-twentieth | 1 |
53 | 0.3g/l | 1 |
54 | ofbuccal | 1 |
55 | brighten | 2 |
56 | benefits.given | 1 |
57 | option-in | 1 |
58 | analysis.in | 2 |
59 | delayed/non-union | 1 |
60 | nonopacification | 1 |
61 | forward-propagation | 1 |
62 | vitiation | 1 |
63 | over-phosphorylation | 1 |
64 | near-elimination | 1 |
65 | -subliminal-presentation | 1 |
66 | solubulization | 1 |
67 | removal/derivatization | 1 |
68 | retroposition | 1 |
69 | self-insertion | 1 |
70 | apap-cpap | 1 |
71 | cgtsq | 1 |
72 | laparotomynumber | 1 |
73 | multitaper | 1 |
74 | management-over | 1 |
75 | tables.for | 1 |
76 | yp/s | 1 |
77 | temperate-latitudes | 1 |
78 | sub-ranges | 1 |
79 | daily-cycles | 1 |
80 | 13cycles | 1 |
81 | research-increases | 1 |
82 | misestimates | 1 |
83 | 18-weeks | 1 |
84 | 11weeks | 1 |
85 | 42weeks | 1 |
86 | 39weeks | 1 |
87 | visuals | 4 |
88 | over-estimations | 1 |
89 | condemnations | 1 |
90 | reorientations | 1 |
91 | confrontations | 1 |
92 | diseases/dysfunctions | 1 |
93 | issuers | 1 |
94 | cholesterol-indicators | 1 |
95 | dha±inhibitors | 1 |
96 | hmgss | 1 |
97 | misjudgements | 1 |
98 | 350mg/kg/day | 1 |
99 | 240mg/day | 1 |
100 | 115.2gy | 1 |
101 | £25,000/qaly | 1 |
102 | pauci-symptomaticity | 1 |
103 | illness/quality | 1 |
104 | palatability/acceptability | 2 |
105 | thesingularity | 1 |
106 | ᅟ | 2 |
107 | 2-6° | 1 |